Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer - Full Text View

Sponsor:	Case Comprehensive Cancer Center
Collaborator:	National Cancer Institute (NCI)
Information provided by (Responsible Party):	Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:	NCT00899132

Purpose

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.

Condition	Intervention
Non-melanomatous Skin Cancer Pancreatic Cancer Small Intestine Cancer Testicular Germ Cell Tumor	Genetic: in situ hybridization Genetic: protein expression analysis Other: immunologic technique

Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Cross-Sectional
Official Title:	The Role of TAB3 Protein in Tumorigenesis

Resource links provided by NLM:

MedlinePlus related topics: Cancer Intestinal Cancer Pancreatic Cancer Skin Cancer Testicular Cancer

U.S. FDA Resources

Further study details as provided by Case Comprehensive Cancer Center:

Primary Outcome Measures:

Identification of TAB3 transcript/protein as a molecular marker of cancer [ Time Frame: end of study ] [ Designated as safety issue: No ]
Characterization of TAB3 and its signaling networks that are involved in tumorigenesis [ Time Frame: end of study ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

Tumor tissue samples from paraffin-embedded tissue blocks.

Estimated Enrollment:	150
Study Start Date:	February 2007
Estimated Primary Completion Date:	December 2012 (Final data collection date for primary outcome measure)

Intervention Details:

Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.

Detailed Description:

OBJECTIVES:

To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer.
To characterize TAB3 and its signaling networks that are involved in tumorigenesis.

OUTLINE: Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Primary care center

Criteria

DISEASE CHARACTERISTICS:

Paraffin tissue blocks from surgical pathology cancer cases, specifically testicular, skin, small intestine, and pancreatic cancer, available

PATIENT CHARACTERISTICS:

Not specified

PRIOR CONCURRENT THERAPY:

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00899132

Locations

United States, Ohio
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center	Recruiting
Cleveland, Ohio, United States, 44106-5065
Contact: Clinical Trials Office - Case Comprehensive Cancer Center 800-641-2422

Sponsors and Collaborators

Case Comprehensive Cancer Center

National Cancer Institute (NCI)

Investigators

Study Chair:

Ge Jin, PhD

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:	NCT00899132 History of Changes
Other Study ID Numbers:	CASE5Y06, P30CA043703, CASE5Y06, CASE-5Y06-CC191
Study First Received:	May 9, 2009
Last Updated:	February 8, 2012
Health Authority:	United States: Federal Government

Keywords provided by Case Comprehensive Cancer Center:

skin cancer
small intestine cancer
pancreatic cancer
malignant testicular germ cell tumor
testicular teratoma

Additional relevant MeSH terms:

Skin Neoplasms
Pancreatic Neoplasms
Testicular Neoplasms
Duodenal Neoplasms
Ileal Neoplasms
Jejunal Neoplasms
Neoplasms, Germ Cell and Embryonal
Intestinal Neoplasms
Neoplasms by Site
Neoplasms
Skin Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases

Pancreatic Diseases
Endocrine System Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Testicular Diseases
Gonadal Disorders
Gastrointestinal Neoplasms
Gastrointestinal Diseases
Duodenal Diseases
Intestinal Diseases
Ileal Diseases
Jejunal Diseases
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on February 09, 2012